Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (Managed Acces Program (MAP))
The Ministry of Science and Higher Education of the Russian Federation (Agreement № 075-15-2021-1086, contract № RF----193021X0015)
Received: 3 May 2021
Accepted: 15 December 2021
First Online: 22 December 2021
: We confirm all relevant ethical guidelines have been followed, and any necessary IRB and ethics committee approvals have been obtained.The study protocol was submitted and approved by the biomedical ethics committee of I.P. Pavlov First Saint Petersburg State Medical University.Informed written consent from all participants was obtained during the study.All necessary and appropriate institutional forms from patients were archived.
: Not applicable.
: I.S.M. had received travel grants from MSD, Novartis, Pfizer, Celgene, Takeda, BMS, consulting fees from Novartis and Celgene, lecturer fees from Novartis, Takeda and Johnson&Johnson.